Tom P Freeman

List of Publications by Year
in descending order

108 papers	5,397 citations	117625 34 h-index	98798 67 g-index
120 all docs	120 docs citations	120 times ranked	4547 citing authors

#	Article	IF	Citations
1	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry,the, 2019, 6, 427-436.	7.4	528
2	New trends in cannabis potency in USA and Europe during the last decade (2008–2017). European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 5-15.	3.2	332
3	Keep off the grass? Cannabis, cognition and addiction. Nature Reviews Neuroscience, 2016, 17, 293-306.	10.2	315
4	Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. British Journal of Psychiatry, 2010, 197, 285-290.	2.8	263
5	Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis. Neuropsychopharmacology, 2010, 35, 1879-1885.	5.4	175
6	The neuropsychopharmacology of cannabis: A review of human imaging studies. , 2019, 195, 132-161.		165
7	Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology, 2020, 45, 1799-1806.	5.4	165
8	Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. European Neuropsychopharmacology, 2015, 25, 325-334.	0.7	145
9	How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neuroscience and Biobehavioral Reviews, 2019, 107, 696-712.	6.1	145
10	Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses. Psychopharmacology, 2016, 233, 3537-3552.	3.1	139
11	Medicinal use of cannabis based products and cannabinoids. BMJ: British Medical Journal, 2019, 365, l1141.	2.3	135
12	'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration. Addiction, 2020, 115, 1207-1216.	3.3	129
13	Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry,the, 2020, 7, 865-874.	7.4	120
14	Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis. Addiction, 2021, 116, 1000-1010.	3.3	116
15	Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?. Addiction, 2014, 109, 1686-1694.	3.3	114
16	Can we make cannabis safer?. Lancet Psychiatry,the, 2017, 4, 643-648.	7.4	114
17	No Smoke without Tobacco: A Global Overview of Cannabis and Tobacco Routes of Administration and Their Association with Intention to Quit. Frontiers in Psychiatry, 2016, 7, 104.	2.6	103
18	Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Translational Psychiatry, 2018, 8, 181.	4.8	102

#	Article	IF	Citations
19	Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence. JAMA Psychiatry, 2020, 77, 1044.	11.0	100
20	Increasing potency and price of cannabis in Europe, 2006–16. Addiction, 2019, 114, 1015-1023.	3.3	96
21	Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction, 2012, 107, 792-800.	3.3	95
22	Associations between cigarette smoking and cannabis dependence: A longitudinal study of young cannabis users in the United Kingdom. Drug and Alcohol Dependence, 2015, 148, 165-171.	3.2	90
23	Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychological Medicine, 2018, 48, 2346-2352.	4.5	83
24	Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction, 2018, 113, 1696-1705.	3.3	81
25	Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates. Lancet Regional Health - Europe, The, 2021, 10, 100227.	5.6	80
26	User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate. Drug and Alcohol Dependence, 2017, 178, 32-38.	3.2	71
27	Effects of increasing cannabis potency on adolescent health. The Lancet Child and Adolescent Health, 2019, 3, 121-128.	5.6	68
28	Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation. Frontiers in Psychiatry, 2014, 5, 149.	2.6	65
29	Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity. Journal of Psychopharmacology, 2019, 33, 822-830.	4.0	60
30	Cannabis and COVID-19: Reasons for Concern. Frontiers in Psychiatry, 2020, 11, 601653.	2.6	59
31	Investigating the interaction between schizotypy, divergent thinking and cannabis use. Consciousness and Cognition, 2012, 21, 292-298.	1.5	53
32	The effects of psychosocial stress on dopaminergic function and the acute stress response. ELife, 2019, 8, .	6.0	53
33	The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. Addiction, 2022, 117, 1510-1517.	3.3	44
34	Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?. Psychological Medicine, 2019, 49, 1574-1580.	4.5	43
35	Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion. International Journal of Neuropsychopharmacology, 2018, 21, 21-32.	2.1	38
36	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study. Psychological Medicine, 2021, 51, 1329-1337.	4.5	38

#	Article	IF	Citations
37	Emotional processing deficits in chronic cannabis use: A replication and extension. Journal of Psychopharmacology, 2014, 28, 466-471.	4.0	37
38	A comparison of emotion regulation strategies in response to craving cognitions: Effects on smoking behaviour, craving and affect in dependent smokers. Behaviour Research and Therapy, 2015, 69, 29-39.	3.1	33
39	Trends in the use of cannabis products in Canada and the USA, 2018 â€" 2020: Findings from the International Cannabis Policy Study. International Journal of Drug Policy, 2022, 105, 103716.	3.3	33
40	Changes in the composition of cannabis from 2000â€"2017 in Denmark: Analysis of confiscated samples of cannabis resin.. Experimental and Clinical Psychopharmacology, 2019, 27, 402-411.	1.8	32
41	Assessing the translational feasibility of pharmacological drug memory reconsolidation blockade with memantine in quitting smokers. Psychopharmacology, 2015, 232, 3363-3374.	3.1	31
42	Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or â€˜ecstasyâ€™ and self-focused compassion: Preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices. Journal of Psychopharmacology, 2015, 29, 961-970.	4.0	30
43	The effects of N-methyl d-aspartate and B-adrenergic receptor antagonists on the reconsolidation of reward memory: A meta-analysis. Neuroscience and Biobehavioral Reviews, 2013, 37, 240-255.	6.1	29
44	Anatomy of a Joint: Comparing Self-Reported and Actual Dose of Cannabis and Tobacco in a Joint, and How These Are Influenced by Controlled Acute Administration. Cannabis and Cannabinoid Research, 2017, 2, 217-223.	2.9	29
45	Ultra-Brief Mindfulness Training Reduces Alcohol Consumption in At-Risk Drinkers: A Randomized Double-Blind Active-Controlled Experiment. International Journal of Neuropsychopharmacology, 2017, 20, 936-947.	2.1	29
46	The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study. Journal of Psychopharmacology, 2020, 34, 981-989.	4.0	26
47	Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme. Addiction Biology, 2020, 25, e12762.	2.6	25
48	Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users. Psychopharmacology, 2017, 234, 3153-3163.	3.1	24
49	Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. Psychological Medicine, 2020, 50, 2364-2373.	4.5	23
50	Weeding out the truth: a systematic review and metaâ€analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence. Addiction, 2022, 117, 284-298.	3.3	20
51	Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532095499.	2.7	19
52	A standard THC unit for reporting of health research on cannabis and cannabinoids. Lancet Psychiatry,the, 2021, 8, 944-946.	7.4	19
53	Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans. Psychopharmacology, 2009, 206, 563-573.	3.1	18
54	Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy. Mindfulness, 2018, 9, 1134-1145.	2.8	18

#	Article	IF	Citations
55	Cannabis and mental health: Prevalence of use and modes of cannabis administration by mental health status. Addictive Behaviors, 2021, 121, 106991.	3.0	18
56	Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review. Psychological Medicine, 2021, 51, 353-364.	4.5	17
57	Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use. Psychopharmacology, 2013, 225, 41-50.	3.1	15
58	Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta‐analysis. Addiction, 2016, 111, 2134-2144.	3.3	15
59	Value‐based decision‐making of cigarette and nondrug rewards in dependent and occasional cigarette smokers: An FMRI study. Addiction Biology, 2020, 25, e12802.	2.6	15
60	Legal regulated markets have the potential to reduce population levels of harm associated with cannabis use. Addiction, 2016, 111, 2091-2092.	3.3	14
61	The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. Journal of Psychopharmacology, 2020, 34, 969-980.	4.0	14
62	Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward. Social Cognitive and Affective Neuroscience, 2015, 10, 85-92.	3.0	13
63	The Acute Effects of a Dopamine D3 Receptor Preferring Agonist on Motivation for Cigarettes in Dependent and Occasional Cigarette Smokers. Nicotine and Tobacco Research, 2018, 20, 800-809.	2.6	13
64	Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence. Psychological Medicine, 2021, 51, 2134-2142.	4.5	13
65	Vaping cannabis (marijuana) has the potential to reduce tobacco smoking in cannabis users. Addiction, 2016, 111, 375-375.	3.3	12
66	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Translational Psychiatry, 2021, 11, 423.	4.8	12
67	Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Translational Psychiatry, 2020, 10, 143.	4.8	11
68	Acute and chronic effects of Î”9-tetrahydrocannabinol (THC) on cerebral blood flow: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109900.	4.8	11
69	Neural responses to reward anticipation and feedback in adult and adolescent cannabis users and controls. Neuropsychopharmacology, 2022, 47, 1976-1983.	5.4	11
70	The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls. Journal of Psychopharmacology, 2022, 36, 1350-1361.	4.0	11
71	Illicit Drug Use and Associated Problems in the Nightlife Scene: A Potential Setting for Prevention. International Journal of Environmental Research and Public Health, 2021, 18, 4789.	2.6	10
72	Individual and combined effects of cannabidiol and Î”^{9}-tetrahydrocannabinol on striato-cortical connectivity in the human brain. Journal of Psychopharmacology, 2022, 36, 732-744.	4.0	10

#	Article	IF	Citations
73	Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?. Neuroscience and Biobehavioral Reviews, 2022, 132, 169-180.	6.1	9
74	The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. Psychopharmacology, 2022, 239, 1539-1549.	3.1	9
75	â€œHow do online and offline sampling compare in a multinational study of drug use and nightlife behaviour?â€• International Journal of Drug Policy, 2020, 82, 102812.	3.3	8
76	Cannabis knowledge and implications for health: Considerations regarding the legalization of non-medical cannabis. Medicine, Science and the Law, 2020, 60, 309-314.	1.0	8
77	A latent class analysis of cannabis use products in a general population sample of adolescents and their association with paranoia, hallucinations, cognitive disorganisation and grandiosity. Addictive Behaviors, 2021, 117, 106837.	3.0	8
78	Dopaminergic involvement in effort-based but not impulsive reward processing in smokers. Drug and Alcohol Dependence, 2013, 130, 109-114.	3.2	7
79	A Moderate Dose of Alcohol Does Not Influence Experience of Social Ostracism in Hazardous Drinkers. Frontiers in Psychology, 2016, 7, 555.	2.1	7
80	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 2021, 51, 2074-2082.	4.5	7
81	Moving forwards with the standard THC unit. Addiction, 2020, 115, 1222-1223.	3.3	7
82	Potent questions about cannabis and mental health. Lancet Psychiatry,the, 2015, 2, 195-196.	7.4	6
83	Bringing together pharmacological and psychological approaches to mental health research. Lancet Psychiatry,the, 2016, 3, 700-702.	7.4	6
84	Restrictions on drugs with medical value: Moving beyond stalemate. Journal of Psychopharmacology, 2018, 32, 1053-1055.	4.0	5
85	Commentary on Salloum <i>et al</i>. (2018): Rethinking adolescent cannabis use and risk perception. Addiction, 2018, 113, 1086-1087.	3.3	5
86	Standard units for cannabis dose: Why is it important to standardize cannabis dose for drug policy and how can we enhance its place on the public health agenda?. International Journal of Drug Policy, 2021, 97, 103350.	3.3	5
87	Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status. Substance Use and Misuse, 2022, 57, 719-729.	1.4	5
88	Cognitive fusion as a candidate psychological vulnerability factor for psychosis: An experimental study of acute âˆ†9-tetrahydrocannabinol (THC) intoxication. Psychosis, 2021, 13, 167-174.	0.8	4
89	Supporting Future Cannabis Policy â€" Developing a Standard Joint Unit: A Brief Back-Casting Exercise. Frontiers in Psychiatry, 2021, 12, 675033.	2.6	4
90	Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis. Journal of Psychopharmacology, 2021, 35, 804-813.	4.0	4

#	Article	IF	Citations
91	Supply always comes on the heels of demand: what effects do control strategies have on drug users themselves?. Addiction, 2012, 107, 1903-1905.	3.3	3
92	Commentary on Meier <i>et al</i>. (2018): Smoke and mirrorsâ€"are adolescent cannabis users vulnerable to cognitive impairment?. Addiction, 2018, 113, 266-267.	3.3	3
93	Minimum THC unit pricing: an opportunity for harm reduction. Addiction, 2021, 116, 232-233.	3.3	3
94	Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Psychopharmacology, 2022, 239, 1349-1357.	3.1	3
95	The iCannToolkit: a tool to embrace measurement of medicinal and nonâ€medicinal cannabis use across licit, illicit and crossâ€cultural settings. Addiction, 2022, , .	3.3	3
96	Rethinking dose-response effects of cannabis use in adolescence. Lancet Psychiatry,the, 2014, 1, 416.	7.4	2
97	Psychiatric Co-morbidity in Ketamine and Methamphetamine Dependence: a Retrospective Chart Review. International Journal of Mental Health and Addiction, 2017, 15, 956-966.	7.4	2
98	Strengthening the evidence for medicinal cannabis and cannabinoids. BMJ: British Medical Journal, 2019, 367, l5871.	2.3	2
99	Cannabidiol for cannabis use disorder: too high hopes? â€" Authors' reply. Lancet Psychiatry,the, 2020, 7, 840.	7.4	2
100	Stimulating meditation: a pre-registered randomised controlled experiment combining a single dose of the cognitive enhancer, modafinil, with brief mindfulness training. Journal of Psychopharmacology, 2021, 35, 621-630.	4.0	2
101	Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees. International Journal of Drug Policy, 2022, 102, 103612.	3.3	2
102	Cannabis and cannabidiol use among autistic and non-autistic adults in the UK: a propensity score-matched analysis. BMJ Open, 2021, 11, e053814.	1.9	2
103	The Effects of Acute Î"9-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 660-667.	1.5	1
104	Evidence from naturalistic studies can be strengthened by triangulation. Addiction, 2022, , .	3.3	1
105	The iCannTookit: A consensusâ€based, flexible framework for measuring contemporary cannabis use. Addiction, 0, , .	3.3	1
106	Reply to Vadhan et al. â€" Correspondence on Curran et al. (2018) â€˜Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like responseâ€™. Psychological Medicine, 2019, 49, 1759-1760.	4.5	0
107	O3.1. ASSOCIATION OF EXTENT OF CANNABIS USE AND ACUTE INTOXICATION EXPERIENCES IN A MULTI-NATIONAL SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS AND CONTROLS. Schizophrenia Bulletin, 2019, 45, S165-S166.	4.3	0
108	Response to Bahji <i>et al</i> .: Limitations of the available evidence that restrict our interpretation of the transition from cannabis to opioid use. Addiction, 0, , .	3.3	0